{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:13:11Z","timestamp":1794247991520,"version":"4.9.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Research Program","award":["5405-B21"],"award-info":[{"award-number":["5405-B21"]}]},{"DOI":"10.13039\/501100002428","name":"Austrian science fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Research Program","award":["5405-B21"],"award-info":[{"award-number":["5405-B21"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>An interrelation between cancer and thrombosis is known, but population-based studies on the risk of both arterial thromboembolism (ATE) and venous thromboembolism (VTE) have not been performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>International Classification of Disease 10th Revision (ICD-10) diagnosis codes of all publicly insured persons in Austria (0\u201390\u2009years) were extracted from the Austrian Association of Social Security Providers dataset covering the years 2006\u201307 (n\u2009=\u20098\u00a0306\u00a0244). Patients with a history of cancer or active cancer were defined as having at least one ICD-10 \u2018C\u2019 diagnosis code, and patients with ATE and\/or VTE as having at least one of I21\/I24 (myocardial infarction), I63\/I64 (stroke), I74 (arterial embolism), and I26\/I80\/I82 (venous thromboembolism) diagnosis code. Among 158\u00a0675 people with cancer, 8559 (5.4%) had an ATE diagnosis code and 7244 (4.6%) a VTE diagnosis code. In contrast, among 8\u00a0147\u00a0569 people without cancer, 69\u00a0381 (0.9%) had an ATE diagnosis code and 29\u00a0307 (0.4%) a VTE diagnosis code. This corresponds to age-stratified random-effects relative risks (RR) of 6.88 [95% confidence interval (CI) 4.81\u20139.84] for ATE and 14.91 (95% CI 8.90\u201324.95) for VTE. ATE proportion was highest in patients with urinary tract malignancies (RR: 7.16 [6.74\u20137.61]) and lowest in patients with endocrine cancer (RR: 2.49 [2.00\u20133.10]). The corresponding VTE proportion was highest in cancer of the mesothelium\/soft tissue (RR: 19.35 [17.44\u201321.47]) and lowest in oropharyngeal cancer (RR: 6.62 [5.61\u20137.81]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The RR of both ATE and VTE are significantly higher in persons with cancer. Our population-level meta-data indicate a strong association between cancer, ATE and VTE, and support the concept of shared risk factors and pathobiology between these diseases.<\/jats:p>\n                  <jats:p>Relative risk of ATE and VTE in persons with a cancer diagnosis code versus persons without a cancer diagnosis code.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab171","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T07:12:40Z","timestamp":1615187560000},"page":"2299-2307","source":"Crossref","is-referenced-by-count":134,"title":["Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer\u2014a nationwide analysis"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-9783","authenticated-orcid":false,"given":"Ella","family":"Grilz","sequence":"first","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria"},{"name":"Department of Anesthesiology and Intensive Care, Danube Hospital , Langobardenstra\u00dfe 122, Vienna 1220, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Posch","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria"},{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz , Auenbruggerplatz 1, Graz 8036, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4504-482X","authenticated-orcid":false,"given":"Stephan","family":"Nopp","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"K\u00f6nigsbr\u00fcgge","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-2692","authenticated-orcid":false,"given":"Irene M","family":"Lang","sequence":"additional","affiliation":[{"name":"Clinical Division of Cardiology, Department of Medicine II, Medical University of Vienna , Waehringer G\u00fcrtel 18-20, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1187-6713","authenticated-orcid":false,"given":"Peter","family":"Klimek","sequence":"additional","affiliation":[{"name":"Section for Science of Complex Systems, CEMSIIS, Medical University of Vienna , Spitalgasse 23, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Thurner","sequence":"additional","affiliation":[{"name":"Section for Science of Complex Systems, CEMSIIS, Medical University of Vienna , Spitalgasse 23, Vienna 1090, Austria"},{"name":"Santa Fe Institute, 1399 Hyde Park Road, Santa Fe , NM 85701, USA"},{"name":"IIASA , Schlossplatz 1, Laxenburg 2361, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"2022102513092359400_ehab171-B1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.12698","article-title":"Thrombosis: a major contributor to the global disease burden","volume":"12","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2022102513092359400_ehab171-B2","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0049-3848(12)70008-7","article-title":"Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients","volume":"129","author":"Ay","year":"2012","journal-title":"Thromb Res"},{"key":"2022102513092359400_ehab171-B3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5482\/HAMO-13-10-0054","article-title":"Platelets in cancer and thrombosis","volume":"34","author":"Riedl","year":"2014","journal-title":"H\u00e4mostaseologie"},{"key":"2022102513092359400_ehab171-B4","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2012.01.005","article-title":"Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Z\u00f6ller","year":"2012","journal-title":"Eur J Cancer"},{"key":"2022102513092359400_ehab171-B5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Z\u00f6ller","year":"2012","journal-title":"Eur J Cancer"},{"key":"2022102513092359400_ehab171-B6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102513092359400_ehab171-B7","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"2022102513092359400_ehab171-B8","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1055\/s-0038-1673401","article-title":"Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer","volume":"118","author":"Grilz","year":"2018","journal-title":"Thromb Haemost"},{"key":"2022102513092359400_ehab171-B9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Internal Med"},{"key":"2022102513092359400_ehab171-B10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","article-title":"Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006","volume":"103","author":"Cronin-Fenton","year":"2010","journal-title":"Br J Cancer"},{"key":"2022102513092359400_ehab171-B11","first-page":"211","article-title":"Arterial thromboembolism in patients with cancer: frequency, risk factors and mortality","volume":"1","author":"Grilz","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"2022102513092359400_ehab171-B12","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0049-3848(14)50007-2","article-title":"Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS)","volume":"133","author":"K\u00f6nigsbr\u00fcgge","year":"2014","journal-title":"Thromb Res"},{"key":"2022102513092359400_ehab171-B13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11739-014-1064-9","article-title":"Cardiovascular oncology: a new discipline inside internal medicine?","volume":"9","author":"Prisco","year":"2014","journal-title":"Intern Emerg Med"},{"key":"2022102513092359400_ehab171-B14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/CIRCRESAHA.116.309573","article-title":"The future of onco-cardiology","volume":"119","author":"Abe","year":"2016","journal-title":"Circ Res"},{"key":"2022102513092359400_ehab171-B15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2005.04.011","article-title":"Age, cancer and the risk of venous thromboembolism","volume":"55","author":"Fimognari","year":"2005","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"2022102513092359400_ehab171-B16","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022102513092359400_ehab171-B17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022102513092359400_ehab171-B18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH06-09-0494","article-title":"Thalidomide and thrombosis. A meta-analysis","volume":"97","author":"El Accaoui","year":"2007","journal-title":"Thromb Haemost"},{"key":"2022102513092359400_ehab171-B19","article-title":"Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","author":"Moik","year":"2020","journal-title":"Blood"},{"key":"2022102513092359400_ehab171-B20","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102513092359400_ehab171-B21","year":"2020"},{"key":"2022102513092359400_ehab171-B22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"key":"2022102513092359400_ehab171-B23","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"2022102513092359400_ehab171-B24","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"2022102513092359400_ehab171-B25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/rth2.12223","article-title":"The risk of arterial thromboembolic events after cancer diagnosis","volume":"3","author":"Navi","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2022102513092359400_ehab171-B26","first-page":"9","article-title":"Epidemiology of cancer-related venous thromboembolism. Best practice & research","volume":"22","author":"Wun","year":"2009","journal-title":"Clin Haematol"},{"key":"2022102513092359400_ehab171-B27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2016.01.002","article-title":"Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study","volume":"139","author":"Ashrani","year":"2016","journal-title":"Thromb Res"},{"key":"2022102513092359400_ehab171-B28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7326\/M17-0868","article-title":"Screening for occult cancer in patients with unprovoked venous thromboembolism","volume":"167","author":"van Es","year":"2017","journal-title":"Ann Intern Med"},{"key":"2022102513092359400_ehab171-B29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B32","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc1313883","article-title":"Edoxaban versus warfarin for venous thromboembolism","volume":"370","author":"Buller","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102513092359400_ehab171-B36","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"Monreal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2022102513092359400_ehab171-B37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12872-018-0932-z","article-title":"Incidence of new onset cancer in patients with a myocardial infarction \u2013 a nationwide cohort study","volume":"18","author":"Malmborg","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2022102513092359400_ehab171-B38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"key":"2022102513092359400_ehab171-B39","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/bmj.38142.554479.AE","article-title":"Mortality in relation to smoking: 50 years' observations on male British doctors","volume":"328","author":"Doll","year":"2004","journal-title":"Br Med J"},{"key":"2022102513092359400_ehab171-B40","first-page":"120","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"Previtali","year":"2011","journal-title":"Blood Transfus"},{"key":"2022102513092359400_ehab171-B41","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"2022102513092359400_ehab171-B42","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/eurheartj\/ehz368","article-title":"Cardio-oncology: a new specialty moves to centre stage","volume":"40","author":"L\u00fcscher","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102513092359400_ehab171-B43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/23\/2299\/46622031\/ehab171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/23\/2299\/46622031\/ehab171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T10:10:23Z","timestamp":1666692623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/23\/2299\/6188996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":43,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,3,26]]},"published-print":{"date-parts":[[2021,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab171","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,14]]},"published":{"date-parts":[[2021,3,26]]}}}